<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02619994</url>
  </required_header>
  <id_info>
    <org_study_id>MDR-END</org_study_id>
    <nct_id>NCT02619994</nct_id>
  </id_info>
  <brief_title>Treatment Shortening of MDR-TB Using Existing and New Drugs</brief_title>
  <acronym>MDR-END</acronym>
  <official_title>Delamanid, Linezolid, Levofloxacin, and Pyrazinamide for the Treatment of Patients With Fluoroquinolone-sensitive MDR-TB: A Phase 2/3, Multicenter, Randomized, Open-label, Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dankook University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Tuberculosis Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pusan National University Yangsan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pusan National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SMG-SNU Boramae Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Incheon St.Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ulsan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korean Institute of Tuberculosis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Medical Center, Seoul</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korean Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of a 'new treatment regimen including
      delamanid, linezolid, levofloxacin, and pyrazinamide for nine or twelve months
      (investigational arm)' and 'the standard treatment regimen including injectables for 20 to 24
      months (control arm)' for treating fluoroquinolone-sensitive multidrug-resistant
      tuberculosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a phase II/III, multicenter, randomized, open-label clinical trial of
      non-inferiority design comparing a new regimen to the World Health Organization-endorsed
      conventional regimen for fluoroquinolone-sensitive MDR-TB. The control arm uses a
      conventional treatment regimen with second-line drugs including injectables for 20-24 months.
      The investigational arm uses a new shorter regimen including delamanid, linezolid,
      levofloxacin, and pyrazinamide for 9 or 12 months depending on time to sputum culture
      conversion. The primary outcome is the treatment success rate at 24 months after treatment
      initiation. Secondary outcomes include time to sputum culture conversion on liquid and solid
      media, proportions of sputum culture conversion on liquid media after 2 and 6 months of
      treatment, treatment success rate according to pyrazinamide resistance, and occurrence of
      adverse events grade 3 and above as evaluated by the Common Terminology Criteria for Adverse
      Events. The population number is calculated as 102 per group (204 in total).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment success rate</measure>
    <time_frame>24 months after treatment start</time_frame>
    <description>To test for non-inferiority of the investigational arm, when the lower limit of the one-sided 97.5% confidence interval of the difference (PT − PC) between investigational and control arms is larger than the non-inferiority margin of − 10%, it will be concluded that the treatment success rate of the investigational arm shows non-inferiority to the treatment success rate of the control arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to sputum culture conversion after treatment start</measure>
    <time_frame>through study completion, 24 months after enrollment</time_frame>
    <description>To determine whether time to sputum culture conversion after treatment start is statis- tically different between the control and investigational arms, the median time will be estimated in each group using the Kaplan-Meier method, and the difference in the distribution of time to culture conversion of the two arms will be compared using the log-rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum culture conversion proportion</measure>
    <time_frame>At 2 months or 6 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment success</measure>
    <time_frame>At 24months after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of reverting to positive sputum culture after the end of treatment</measure>
    <time_frame>At 24months after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment success according to pyrazinamide resistance</measure>
    <time_frame>At 24months after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of death between the control and investigational arms</measure>
    <time_frame>At 24months after enrollment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">238</enrollment>
  <condition>Tuberculosis, Multidrug-Resistant</condition>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Regimen is the locally-used WHO-approved MDR-TB regimen in Korea based on 2014 Korean guideline of TB management.
Intensive phase regimen consists of four effective second-line anti-TB drugs (including injectables) and pyrazinamide.
Treatment duration: for at least 20 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regimen consists of only oral medication using delamanid, linezolid, levofloxacin, and pyrazinamide, for nine or twelve months depending on the time of sputum culture conversion to negative.
Delamanid (100 mg bid for the entire treatment period)
Linezolid (600mg/day for 2 months and 300mg/day afterwards until the end of treatment)
Levofloxacin (750 ~1000 mg/day)
Pyrazinamide (1000~ 2000 mg/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linezolid</intervention_name>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delamanid</intervention_name>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin</intervention_name>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrazinamide</intervention_name>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Locally-used WHO-approved MDR-TB regimen in Korea</intervention_name>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females aged from 19 to 85 years

          -  Confirmed MDR-TB or RR-TB

          -  On current TB therapy for ≤14 days at the time of enrollment.

        Exclusion Criteria:

          -  Known any quinolone-resistant MDR-TB

          -  Known XDR-TB

          -  who are pregnant or who are unwilling to use proper contraceptives at childbearing age

          -  Medical history of galactose intolerance, Lapp lactase deficiency, glucose-galactose
             malabsorption

          -  The need for ongoing use of prohibited drugs while on study drugs

          -  History of optic neuropathy or peripheral neuropathy

          -  With any of the following test results: i.Absolute neutrophil count &lt; 2000 cells/mL,
             ii.White blood cell count (WBC) &lt; 3.0 X 103/µL, iii.Hemoglobin &lt; 7.0 g/dL, iv.Serum
             creatinine &gt; 2.0 mg/dL, v.Aspartate aminotransferase (AST or SGOT) &gt;100 IU/L,
             vi.Alanine aminotransferase (ALT or SGPT) &gt;100 IU/L, vii.Total bilirubin &gt; 2.0 mg/dL,
             viii.Albumin &lt; 2.8g/dL, ix.QTcF &gt; 500ms

          -  History of hypersensitivity reaction to the study drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jae-Joon Yim, MD</last_name>
    <phone>+82-2-2072-2059</phone>
    <email>yimjj@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae-Joon Yim, MD</last_name>
      <phone>+82-2-2072-2059</phone>
      <email>yimjj@snu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>November 24, 2015</study_first_submitted>
  <study_first_submitted_qc>November 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2015</study_first_posted>
  <last_update_submitted>January 31, 2019</last_update_submitted>
  <last_update_submitted_qc>January 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jae-Joon Yim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Multidrug-resistant tuberculosis</keyword>
  <keyword>Linezolid</keyword>
  <keyword>Delamanid</keyword>
  <keyword>Multicenter randomized trial</keyword>
  <keyword>Non-inferiority</keyword>
  <keyword>Shorter regimen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Pyrazinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

